233 related articles for article (PubMed ID: 7896540)
1. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
2. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
3. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
[TBL] [Abstract][Full Text] [Related]
4. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Cabanillas F; Rodriguez MA
Semin Hematol; 1994 Apr; 31(2 Suppl 3):30. PubMed ID: 8073305
[No Abstract] [Full Text] [Related]
5. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Rodriguez-Monge EJ; Cabanillas F
Hematol Oncol Clin North Am; 1997 Oct; 11(5):937-47. PubMed ID: 9336723
[TBL] [Abstract][Full Text] [Related]
9. Experience with salvage regimens at M.D. Anderson Hospital.
Cabanillas F
Ann Oncol; 1991 Jan; 2 Suppl 1():31-2. PubMed ID: 1904269
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
Fernández de Larrea C; Martínez C; Gaya A; López-Guillermo A; Rovira M; Fernández-Avilés F; Lozano M; Bosch F; Esteve J; Nomdedeu B; Montserrat E; Carreras E
Ann Oncol; 2010 Jun; 21(6):1211-1216. PubMed ID: 19889622
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Cabanillas F
Semin Oncol; 1992 Feb; 19(1 Suppl 1):11-3. PubMed ID: 1384134
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Wilder RB; Rodriguez MA; Tucker SL; Ha CS; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):743-9. PubMed ID: 11395243
[TBL] [Abstract][Full Text] [Related]
14. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
15. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
Velasquez WS; McLaughlin P; Tucker S; Hagemeister FB; Swan F; Rodriguez MA; Romaguera J; Rubenstein E; Cabanillas F
J Clin Oncol; 1994 Jun; 12(6):1169-76. PubMed ID: 8201379
[TBL] [Abstract][Full Text] [Related]
16. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
[TBL] [Abstract][Full Text] [Related]
17. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Rodriguez J; Preti A; Younes A; Sarris AH; Cabanillas F
Invest New Drugs; 1999; 17(2):187-92. PubMed ID: 10638491
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Emmanouilides C; Lill M; Telatar M; Rosenfelt F; Grody W; Territo M; Rosen P
Clin Lymphoma; 2002 Sep; 3(2):111-6. PubMed ID: 12435284
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
